GlassScriptPhysician profile
Keith Emery Kellum
NPI 1225036023
$10,204.89
in general payments reported to CMS, 2019-2025
33 companies · $2,690 in 2025
The $2,690 reported for 2025 was more than what 91% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $999 · 2020: $569 · 2021: $1,534 · 2022: $1,360 · 2023: $1,646 · 2024: $1,406 · 2025: $2,690.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,716 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,716.06 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,058.68 | 2019-2025 | Hydrus Microstent, Rocklatan, Tryptyr |
| Abbvie INC. | $1,474.20 | 2022-2025 | |
| Allergan, INC. | $832.33 | 2019-2022 | |
| Ivantis, INC | $807.55 | 2020-2021 | |
| Sight Sciences, INC. | $738.29 | 2021-2025 | Omni Surgical System, Tearcare System, Sion Surgical Instrument |
| Lumenis Be INC | $663.22 | 2025 | M22 |
| Oyster Point Pharma, INC. | $483.90 | 2022-2025 | Tyrvaya, Ryzumvi |
| Glaukos Corporation | $320.83 | 2021-2025 | Idosetr |
| Bausch & Lomb Americas INC. | $284.32 | 2022-2025 | Miebo, Infuse, Lotemax Sm |
| Sun Pharmaceutical Industries INC. | $260.53 | 2019-2025 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $249.96 | 2019-2021 | |
| New World Medical,INC. | $232.43 | 2025 | Ahmed Glaucoma Valve, Streamline, Via360 |
| Dompe US, INC. | $183.94 | 2024-2025 | Oxervate |
| Regeneron Healthcare Solutions, INC. | $155.74 | 2019-2025 | Eylea Hd |
| Harrow Eye, LLC | $154.26 | 2024-2025 | Vevye, Iheezo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iridex Corporation | $149.61 | 2024 | |
| Amgen INC. | $144.41 | 2024-2025 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $122.05 | 2020-2024 | Catalys System |
| Apellis Pharmaceuticals, INC. | $120.98 | 2023-2025 | Syfovre |
| Aerie Pharmaceuticals, INC. | $94.26 | 2019-2021 | |
| Carl Zeiss Meditec USA, INC. | $94.15 | 2023 | Callisto Eye |
| Rxsight INC | $93.32 | 2022-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Biotissue Holdings INC. | $83.44 | 2019-2025 | |
| Kala Pharmaceuticals, INC. | $75.77 | 2020-2021 | |
| Genentech USA, INC. | $54.36 | 2022 | |
| Novartis Pharmaceuticals Corporation | $47.40 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $45.70 | 2024-2025 | Xdemvy |
| Mallinckrodt Hospital Products INC. | $44.39 | 2021 | |
| Horizon Therapeutics Plc | $35.91 | 2023 | Tepezza |
| Rayner Intraocular Lenses Limited | $31.56 | 2023 | Rayone Spheric, Omidria, Rayone Emv |
| Ocular Therapeutix, INC. | $29.50 | 2022 | |
| Coherus Oncology, INC. | $24.52 | 2023 | |
| Johnson & Johnson Vision Care, INC. | $13.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Kellum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.